Brief: Prescient Therapeutics Says It Entered Manufacturing Services Agreement
16/08/2022 02:27
Aug 16 (Reuters) - Prescient Therapeutics Ltd PTX.AX :
* ENTERED A MANUFACTURING SERVICES AGREEMENT WITH Q-GEN CELL
THERAPEUTICS
* AGREEMENT TO PRODUCE OMNICAR CELL LINES FOR UPCOMING
CLINICAL
TRIALS
Source text for Eikon: ID:nASX6nj8sn
Further company coverage: PTX.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Prescient Therapeutics
See all newsAustralia's Prescient Therapeutics falls on discounted share placement
Brief: Prescient Therapeutics Raises A$4.8 Million Via SPP, A$1.2 Million In Placement
Brief: Prescient Therapeutics Says Trading Halt Requested
Australia's Prescient Therapeutics hits near 2-month low on discounted raise
Brief: Prescient Therapeutics Secures EU Authorisation To Commence PTX-100 Clinical Trial